ViGeneron GmbH has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases.
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. have announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.